Vicky Makker

Vicky Makker led the KEYNOTE-775 trial that established lenvatinib plus pembrolizumab as standard of care for advanced endometrial cancer after prior platinum-based chemotherapy, representing the first major survival benefit in the second-line setting. This combination achieved FDA approval in 2021 and became incorporated into international treatment guidelines. Her subsequent research has investigated predictive biomarkers, resistance mechanisms, and alternative checkpoint combinations for endometrial cancer. She is the primary investigator for multiple MSK endometrial cancer clinical trials.